БЛОГ

Aug 17, 2019

PALM Ebola Clinical Trial Stopped Early as Regeneron’s REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths

Posted by in category: biotech/medical

TARRYTOWN, N.Y., Aug. 12, 2019 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Company was informed by study investigators that a randomized, controlled trial evaluating four investigational therapies for Ebola virus infection was stopped early because.

Comments are closed.